Schäfer
Fakultäten » Medizinische Fakultät » Kinderspital Zürich: Medizinische Klinik » Onkologie, Abteilung » Prof. Dr. Felix Niggli » Schäfer
Completed research project
| Title / Titel | Molecular basis of sarcoma tumor development | ||
|---|---|---|---|
| Abstract (PDF, 14 KB) | |||
| Summary / Zusammenfassung | Using mainly a pediatric soft tissue sarcoma (rhabdomyosarcoma) as tumor model, we are working to elucidate the molecular mechanisms underlying tumor cell development. Novel insights into these mechanisms are used to advance prognosis and treatment in patients. In particular, we follow the hypothesis that oncogenic transcription factors of the PAX family can serve as novel drug targets in different types of tumors. The work at the interface between basic research and clinical applications covers the following specific aims: - Characterization of target genes activated by the chimaeric transcription factor PAX3/FKHR generated by chromosomal translocation t(2;13) and native paired box containing transcription factors. - Control of PAX3/FKHR activity through post-translational modifications. - Generation of a mouse model for alveolar rhabdomyosarcoma. - Development of novel targeted treatment strategies. - Identification of cancer stem cells. - In collaboration with the clinics, the potential use of novel tumor markers for advanced diagnosis of soft tissue sarcomas is investigated. Weitere Informationen |
||
| Publications / Publikationen | Amstutz RA, WachtelM, Troxler H, Kleinert P, Ebauer M, Oehler C, Fabbro D, Niggli FK and Schäfer BW (2008) Specific phosphorylation events regulate transcriptional activity of PAX3/FKHR and reveal novel therapeutic possibilities, Cancer Research 68, 3767-3776Ebauer M, Wachtel M, Niggli FK, Schäfer BW (2007) Comparative expression profiling identifiesTFAP2beta as an essential in vivo target of PAX3/FKHR. Oncogene, 26, 7267-7281.Wachtel M, Runge T, Leuschner I, Koscielniak E, Stegmaier S, Treuner J, Odermatt B, Behnke S, Niggli FK, Schäfer BW (2006) Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry, J Clin Oncology, 24, 816-822.Wachtel, M. Dettling, M. Koscielniak, E., Stegmaier, S., Treuner, J., Simon-Klingenstein, K., Bühlmann, P., Niggli, F.K., Schäfer, B.W. (2004) Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Research 64, 5539-5545.Relaix, F., Polimeni, M., Rocancourt, D., Ponzetto, C., Schäfer, B.W., Buckingham, M. (2003) The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain of function phenotype with ligand-independent activation of Met signaling in vivo. Genes & Development, 17, 2950-2965.Scholl, F.A., Kamarashev J., Murmann, O.V., Geertsen, R., Dummer, R., and Schäfer, B.W. (2001) PAX3 is expressed in human melanomas and contributes to tumor cell survival, Cancer Research 61, 823-826. | ||
| Keywords / Suchbegriffe | cancer research, chromosomal translocation, PAX proteins, rhabdomyosarcoma, mouse tumor model, expression profiling, siRNA, cancer stem cells | ||
| Project leadership and contacts / Projektleitung und Kontakte |
|
||
| Other links to external web pages | http://www.kispi.uzh.ch/onkologie | ||
| Funding source(s) / Unterstützt durch |
SNF (Personen- und Projektförderung), Foundation, Others OncoSuisse, Krebliga des Kt. Zürich |
||
| Duration of Project / Projektdauer | Jan 2007 to Dec 2010 |